Comparative Study of Indian Patent Law vs US, UK & EU Patent Regimes: A Supreme Court Perspective
Part C
Comparative Study: Indian Patent Law vs US, UK & EU Patent Regimes
1. Introduction
Patent systems across jurisdictions aim to balance innovation incentives with public interest, but they differ significantly in patentability standards, enforcement, and policy orientation.
India follows the Patents Act, 1970, while the US, UK, and EU operate under:
U.S. Patent Act
UK Patents Act 1977
European Patent Convention (EPC)
2. Comparative Table (Core Features)
| Feature | India | USA | UK | EU (EPO) |
|---|---|---|---|---|
| Governing Law | Patents Act, 1970 | Title 35 USC | Patents Act 1977 | EPC |
| Patent Term | 20 years | 20 years | 20 years | 20 years |
| Filing System | First-to-file | First-to-file (post AIA) | First-to-file | First-to-file |
| Patentable Subject Matter | Restricted (Sec 3) | Broad | Moderate | Moderate |
| Software Patents | Not patentable per se | Allowed | Allowed (technical effect) | Allowed (technical effect) |
| Pharma Patents | Strict (Sec 3(d)) | Liberal | Moderate | Moderate |
| Compulsory Licensing | Strong | Rare | Limited | Limited |
| Pre-grant Opposition | Yes | No | No | No |
| Post-grant Opposition | Yes | Yes (PTAB) | Limited | Yes (EPO Opposition) |
3. Patentability Standards
(A) India
Governed by Section 2(1)(j) (invention) and Section 3 exclusions.
Strict exclusion under Section 3(d) (pharmaceutical patents).
Key Case
Novartis AG v. Union of India
Citation: (2013) 6 SCC 1
Prevents "evergreening" of patents.
(B) USA
Broad patent eligibility under 35 U.S.C. §101.
However, subject to judicial restrictions.
Key Case
Alice Corp. v. CLS Bank International
Citation: 573 U.S. 208
Abstract ideas (including software) are not patentable without an inventive concept.
(C) UK
Based on EPC principles.
Requires a technical contribution.
Key Case
Aerotel Ltd v Telco Holdings Ltd
Established a structured test for patentability.
(D) EU (EPO)
Governed by Article 52 of the European Patent Convention.
Focuses on technical character.
Key Case
T 641/00 (COMVIK Approach)
Only technical features are considered when assessing inventive step.
4. Pharmaceutical Patents – A Key Difference
| Jurisdiction | Approach |
|---|---|
| India | Very Strict (Section 3(d)) |
| USA | Liberal (Incremental Innovation Allowed) |
| UK/EU | Moderate |
Indian Position
Incremental innovation must demonstrate enhanced efficacy.
Protects public health and the generic pharmaceutical industry.
5. Software & Business Method Patents
| Jurisdiction | Position |
|---|---|
| India | Not Patentable Per Se |
| USA | Allowed with Limitations |
| UK/EU | Allowed if Technical Effect is Shown |
Indian Law
Section 3(k) excludes:
Algorithms
Business methods
India adopts a much stricter approach than the US and EU.
6. Compulsory Licensing
India
Strong provision under Section 84.
Used in public interest.
Case
Bayer Corporation v. Natco Pharma Ltd.
First compulsory licence granted for a cancer drug.
USA / UK / EU
Rarely used.
Generally reserved for exceptional or emergency situations.
7. Opposition Mechanism
| Type | India | USA | UK | EU |
|---|---|---|---|---|
| Pre-grant | Yes | No | No | No |
| Post-grant | Yes | Yes (PTAB) | Limited | Yes |
India has one of the strongest opposition systems among major patent jurisdictions.
8. Enforcement & Litigation
India
Civil suits under patent law.
Growing jurisprudence in Indian High Courts.
Key Case
Enercon (India) Ltd. v. Aloys Wobben
Citation: (2014) 5 SCC 1
USA
Strong enforcement mechanisms.
High damages awards and jury trials.
UK/EU
Specialized patent courts.
Centralized grant through the EPO, with national enforcement.
9. Procedure Comparison
| Stage | India | USA | UK/EU |
|---|---|---|---|
| Filing | Yes | Yes | Yes |
| Publication | 18 Months | 18 Months | 18 Months |
| Examination | On Request | Automatic | Automatic |
| Grant Time | 2–5 Years | 2–4 Years | 2–4 Years |
India requires filing a Request for Examination (RFE).
10. Policy Orientation
| Jurisdiction | Policy Focus |
|---|---|
| India | Public Interest and Access to Medicines |
| USA | Innovation and Commercialization |
| UK/EU | Balanced Approach |
11. Impact on Business & Strategy
India
Ideal for:
Generic pharmaceutical companies
Cost-sensitive innovation
USA
Strong protection for:
High-technology companies
Software and biotechnology sectors
UK/EU
Balanced environment for:
Manufacturing industries
Engineering sectors
12. Key Differences (Summary)
India is Unique Because:
Strict patentability standards under Section 3
Strong compulsory licensing provisions
Pre-grant opposition mechanism
USA is Unique Because:
Broad patent scope
High damages awards
Strong enforcement mechanisms
UK/EU are Unique Because:
Technical effect requirement
Harmonized patent framework through the EPO
13. Strategic Takeaways for Businesses
Pharmaceutical companies often prefer India for generic manufacturing opportunities.
Technology companies may prefer the USA for broader patent protection.
Global businesses frequently file patents across multiple jurisdictions.
Patent strategies should be tailored to each jurisdiction's legal framework.
Conclusion
The Indian patent system under the Patents Act, 1970 is distinctly public-interest oriented, particularly in the pharmaceutical sector, while the US and EU systems are generally more innovation-driven and market-oriented.
A comparative understanding of these jurisdictions helps businesses:
Optimize patent filing strategies.
Reduce litigation risks.
Maximize global intellectual property protection.
Blog by:
Jayprakash B. Somani
Advocate, Supreme Court of India & President of NPNLC
Cell: PA 9322188701
